The breakthrough and the future: CD20 chimeric antigen receptor T‐cell therapy for hematologic malignancies
ImmunoMedicine · 2022
DOI: 10.1002/imed.1039 ↗Kurz gefasst
Fachartikel in der Zeitschrift ImmunoMedicine, 2022. Verfasst von Elaine Tan Su Yin und 2 weiteren Autor:innen. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Chimeric antigen receptors (CAR) T‐cell therapy is one of the most effective treatments in curing hematologic malignancies. Besides the four CD19 CAR T‐cells therapy recently approved by the US Food and Drug Administration (FDA), CD20 CAR T‐cell therapy is now another effective treatment option for relapsed or refractory non‐Hodgkin lymphoma (NHL). CD20 CAR T‐cell infusion has achieved remarkable clinical outcomes in patients with B‐cell malignancies. This review will cover the current situations, advantages, limitations, prospects, and application of CD20 CAR T‐cell therapy.
Zitieren
APA
Yin, E. T. S., Hu, Y. X., & Huang, H. (2022). The breakthrough and the future: CD20 chimeric antigen receptor T‐cell therapy for hematologic malignancies. ImmunoMedicine. https://doi.org/10.1002/imed.1039
Vancouver
Yin ETS, Hu YX, Huang H. The breakthrough and the future: CD20 chimeric antigen receptor T‐cell therapy for hematologic malignancies. ImmunoMedicine. 2022. doi:10.1002/imed.1039
BibTeX
@article{Yin2022,
author = {Yin, Elaine Tan Su and Hu, Yong Xian and Huang, He},
title = {The breakthrough and the future: CD20 chimeric antigen receptor T‐cell therapy for hematologic malignancies},
journal = {ImmunoMedicine},
year = {2022},
doi = {10.1002/imed.1039}
}
EUVIMED